US BIOLOGICS DRUG-SUBSTANCE SCREEN
Which US CDMO site fits your protein biologic program?
Compare published US facility scope, bioreactor scale, and supply stage across ten reviewed facilities/networks before sending a technical RFI.
| Site | Process & modality scope | Disclosed site scale | Supply stage |
|---|---|---|---|
Lonza VacavilleVacaville | multi-product cGMP mammalian manufacturing facility | total capacity of 332,000L | late-stage clinical (Phase 3) and commercial supply |
Lonza PortsmouthPortsmouth, New Hampshire, USA | custom production of mammalian biopharmaceuticals; GS-system for monoclonal antibodies and recombinant proteins | 6,000L and 20,000L stainless steel bioreactors | clinical and commercial manufacturing |
FUJIFILM Holly SpringsHolly Springs, North Carolina, US | Commercial-scale mammalian cell culture; monoclonal antibodies.Vendor announcement July 8, 2026; product-specific qualification still required.Source & date | 8 × 20,000 L mammalian reactors openedAnother 8 targeted for late FY2027; not included as current capacity.Source & date | Commercial-scale mammalian cell culture; monoclonal antibodies.Vendor announcement July 8, 2026; product-specific qualification still required.Source & date |
Samsung Biologics RockvilleRockville CampusAcquired from GSK 2026-03-31 | Protein-specific scope unknown in reviewed sources | 60,000 L ; provides 60 kL capacity | Clinical and commercial biologics manufacturing (acquired from GSK Mar 31, 2026) |
WuXi Biologics WorcesterWorcester, Massachusetts (plus Cranbury, New Jersey), USA | single-use biologics drug substance manufacturing | 36,000L (6 x 6,000L) single-use capacity; up to 12,000L per batch | clinical- and commercial-scale cGMP manufacturing |
Catalent Madison & BloomingtonMadison, Wisconsin and Bloomington, Indiana, USADisclosed 2021-04-13; current operations unconfirmed | mammalian cell line technology (GPEx) and development/manufacturing for new biological entities and biosimilars | Madison: 100 to 4,000-liter single-use (three 2x2,000L, 1,000L, 500L); Bloomington: two 2,500L stainless steel + 1,000L single-use | clinical and commercial CGMP manufacturing |
AGC Biologics SeattleSeattle, Washington, USANamed-site mammalian equipment now documented | Seattle-specific GMP mammalian manufacturing and cell-line development.Named-site claim; molecule-specific suite fit and availability unknown.Source & date | 9 × 2,000 L single-use; 3,000 L stainless steelSeattle-specific equipment; simultaneous batch capacity and bookable slots unknown.Source & date | network-disclosed pre-clinical, clinical, and commercial programs (Seattle site-level stage confirmation pending) |
Avid Bioservices Costa MesaCosta Mesa, California, USAEarly-phase campus; Tustin handles clinical/commercial scope | CHO/HEK293 cell-line and DNA-to-IND process development.Facility development scope; manufacturing train and volume remain unknown.Source & date | Bioreactor volume not published on reviewed page | Costa Mesa: early phase. Tustin: clinical and commercial manufacturing.Separate campuses; confirm the transfer and manufacturing locations in the proposal.Source & date |
Curia (US facilities)United States facilities (city not named on capability page) | antibodies, proteins, enzymes, and mRNA; stable mammalian cell line development | Bioreactor volume not published on reviewed page | IND to commercial-ready cGMP manufacturing |
Abzena BristolBristol, Pennsylvania, USABioconjugates/ADCs focus | bioconjugates and ADCs (antibodies, linker payloads, bioconjugation) | Bioreactor volume not published on reviewed page | clinical and commercial cGMP bioconjugate use |
Editorial qualification question (not a vendor claim): Does sponsor US supply-chain / BIOSECURE procurement policy apply to your program? Applicability is unknown from saved vendor facility pages (including WuXi Biologics); confirm sponsor eligibility separately.